Literature DB >> 6978875

Functional and antigenic properties of cultured T cells in the cell mediated lympholysis (CML) assay.

K S Zier.   

Abstract

Cultured T cells (CTC) were expanded in Interleukin-2 (IL-2) and used as reagents in cell mediated lympholysis (CML). CTC were able to induce the generation of primary cytotoxic effector cells and to function as 51Cr labeled target cells and cold target inhibitors. Since large numbers of CTC can be produced from as few as 1-2 X 10(6) lymphocytes within a short period of time, these reagents will enable CML studies to be performed in a broader range of situations, including those with were heretofore impossible.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978875     DOI: 10.1016/0198-8859(82)90014-3

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  5 in total

1.  Human lung tumor cell secretion of interleukin-2 for protection against tumor engraftment.

Authors:  T Alosco; B Gansbacher; R Bankert; H Takita; N Petrelli
Journal:  Ann Surg Oncol       Date:  1994-05       Impact factor: 5.344

2.  Antitumor response independent of functional B or T lymphocytes induced by the local and sustained release of interleukin-2 by the tumor cells.

Authors:  T Alosco; B A Croy; B Gansbacher; H Q Wang; U Rao; R Bankert
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

3.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.

Authors:  B Gansbacher; K Zier; B Daniels; K Cronin; R Bannerji; E Gilboa
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

4.  Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2.

Authors:  I Hara; H Hotta; N Sato; H Eto; S Arakawa; S Kamidono
Journal:  Jpn J Cancer Res       Date:  1996-07

5.  Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells.

Authors:  J Connor; R Bannerji; S Saito; W Heston; W Fair; E Gilboa
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.